Abstract
As indicated by its name, tumor necrosis factor (TNF), cloned in 1985, was originally described as a macrophage-derived endogenous mediator that can induce hemorrhagic necrosis of solid tumors and kill some tumor cell lines in vitro. Unfortunately, its promising use as an anticancer agent was biased by its toxicity, which was clear soon from the first clinical trials with TNF in cancer. Almost at the same time TNF was being developed as an anticancer drug, it became clear that TNF was identical to a mediator responsible for cachexia associated with sepsis, which was termed cachectin. This research led to the finding that TNF is, in fact, the main lethal mediator of sepsis and to the publication of a huge number of articles showing that TNF inhibits the toxic effects of bacterial endotoxins, which are now described as systemic inflammatory response. Although the clinical trials with anti-TNF in sepsis have not been successful thus far, undoubtedly as a result of the complexity of this clinical setting, these studies ultimately led to the identification of TNF as a key inflammatory mediator and to the development of anti-TNF molecules (soluble receptors and antibodies) for important diseases including rheumatoid arthritis and Crohn’s disease. On the other side, the mechanisms by which TNF and related molecules induce cell death have been studied in depth, and their knowledge might, in the future, suggest means of improve the therapeutic index of TNF in cancer.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Beutler, B., Milsark, I. W., and & Cerami, A. C. (1985) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229, 869–871.
Tracey, K. J., Fong, Y., Hesse, D. G., et al. (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330, 662–664.
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med. 20, 864–874.
Dayer, J. M., Beutler, B., and Cerami, A. (1985) Cachectin/tumor necrosis factor stimulates collage-nase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J. Exp. Med. 162, 2163–2168.
Saklatvala, J. (1986) Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322, 547–549.
Seckinger, P., Isaaz, S., and Dayer, J. M. (1988) A human inhibitor of tumor necrosis factor alpha. J. Exp. Med. 167, 1511–1516.
Seckinger, P., Zhang, J. H., Hauptmann, B., and Dayer, J. M. (1990) Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor. Proc. Natl. Acad. Sci. USA 87, 5188–5192.
Engelmann, H., Novick, D., and Wallach, D. (1990) Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J. Biol. Chem. 265, 1531–1536.
Beutler, B., Krochin, N., Milsark, I. W., Luedke, C., and Cerami, A. (1986) Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 232, 977–980.
Busso, N., Collart, M., Vassalli, J. D., and Belin, D. (1987) Antagonist effect of RU 486 on transcription of glucocorticoid-regulated genes. Exp. Cell Res. 173, 425–430.
Di Santo, E., Sironi, M., Mennini, T., et al. (1996) A glucocorticoid receptor-independent mechanism for neurosteroid inhibition of tumor necrosis factor production. Eur. J. Pharmacol. 299, 179–186.
Swingle, W. W. and Remington, J. W. (1944) Role of adrenal cortex in physiological processes. Physiol. Rev. 24, 89–127.
Abernathy, R. S., Halberg, F., and Spink, W. W. (1957) Studies on mechanism of chloropromazine protection against Brucella endotoxin. J. Lab. Clin. Med. 49, 708–715.
Lazar, G. and Agarwal, M. K. (1986). The influence of a novel glucocorticoid antagonist on endotoxin lethality in mice strains. Biochem. Med. Metab. Biol. 36, 70–74.
Lazar, G. J., Duda, E., and Lazar, G. (1992) Effect of RU 38486 on TNF production and toxicity. FEBS Lett. 308, 137–140.
Perlstein, R. S., Whitnall, M. H., Abrams, J. S., Mougey, E. H., and Neta, R. (1993) Synergistic roles of interleukin-6, interleukin-1, and tumor necrosis factor in the adrenocorticotropin response to bacterial lipopolysaccharide in vivo. Endocrinology 132, 946–952.
Kunkel, S. L., Spengler, M., May, M. A., Spengler, R., Larrick, J., and Remick, D. (1988) Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression. J. Biol. Chem. 263, 5380–5384.
Spinas, G. A., Bloeash, D., Keller, U., Zimmerli, W., and Cammisuli, S. (1991) Pretreatment with ibuprofen augments circulating tumor necrosis factor-a, interleukin-6, and elastase during acute endotoxemia. J. Infect. Dis. 163, 89–95.
Martich, G. D., Danner, R. L., Ceska, M., and Suffredini, A. F. (1991) Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. J. Exp. Med. 173, 1021–1024.
Gérard, C., Bruyns, C., Marchant, A., et al. (1993) Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J. Exp. Med. 177, 547–550.
de Waal-Malefyt, R., Abrams, J., Bennet, B., Figdor, C., and de Vries, J. E. (1991) Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174, 1209–1220.
Gautam, S., Tebo, J. M., and Hamilton, T. A. (1992) IL-4 suppresses cytokine gene expression induced by IFN-gamma and/or IL-2 in murine peritoneal macrophages. J. Immunol. 148, 1725–1730.
de Waal Malefyt, R., Figdor, C. G., Huijbens, R., et al. (1993) Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J. Immunol. 151, 6370–6381.
Dumoutier, L. and Renauld, J. C. (2002) Viral and cellular interleukin-10 (IL-10)-related cytokines: from structures to functions. Eur. Cytokine Netw. 13, 5–15.
Borovikova, L. V., Ivanova, S., Zhang, M., et al. (2000) Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405, 458–462.
Tracey, K. J. (2002) The inflammatory reflex. Nature 420, 853–859.
Staal, F. J., Roederer, M., and Herzenberg, L. A. (1990) Intracellular thiols regulate activation of nuclear factor kappa B and transcription of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 87, 9943–9947.
Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A., and Karin, M. (1995) Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270, 286–290.
Kopp, E. and Ghosh, S. (1994) Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265, 956–959.
Moss, M. L., White, J. M., Lambert, M. H., and Andrews, R. C. (2001) TACE and other ADAM proteases as targets for drug discovery. Drug Discov. Today 6, 417–426.
Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A., and Kaplan, G. (1991) Thalidomide selectively inhibts tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 173, 699–703.
Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., and Kaplan, G. (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med. 177, 1675–1680.
Lee, J. C., Laydon, J. T., McDonnell, P. C., et al. (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739–746.
Bianchi, M., Bloom, O., Raabe, T., et al. (1996) Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J. Exp. Med. 183, 927–936.
Cohen, P. S., Schmidtmayerova, H., Dennis, J., et al. (1997) The critical role of p38 MAP kinase in T cell HIV-1 replication. Mol. Med. 3, 339–346.
Hommes, D., van den Blink, B., Plasse, T., et al. (2002) Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn’s disease. Gastroenterology 122, 7–14.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ghezzi, P., Cerami, A. Tumor necrosis factor as a pharmacological target. Mol Biotechnol 31, 239–244 (2005). https://doi.org/10.1385/MB:31:3:239
Issue Date:
DOI: https://doi.org/10.1385/MB:31:3:239